Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 56 citing articles:

Evaluation of Waning of SARS-CoV-2 Vaccine–Induced Immunity
Francesco Menegale, Mattia Manica, Agnese Zardini, et al.
JAMA Network Open (2023) Vol. 6, Iss. 5, pp. e2310650-e2310650
Open Access | Times Cited: 178
Mechanisms of PANoptosis and relevant small-molecule compounds for fighting diseases
Lian Wang, Yanghui Zhu, Lu Zhang, et al.
Cell Death and Disease (2023) Vol. 14, Iss. 12
Open Access | Times Cited: 35
A Systematic Review and Meta-Analysis on the Real-World Effectiveness of COVID-19 Vaccines against Infection, Symptomatic and Severe COVID-19 Disease Caused by the Omicron Variant (B.1.1.529)
Hassen Mohammed, Dan Duy Pham-Tran, Zi Yi Michelle Yeoh, et al.
Vaccines (2023) Vol. 11, Iss. 2, pp. 224-224
Open Access | Times Cited: 34
Effectiveness of SARS-CoV-2 vaccines against Omicron infection and severe events: a systematic review and meta-analysis of test-negative design studies
Shangchen Song, Zachary J. Madewell, Ming‐Jin Liu, et al.
Frontiers in Public Health (2023) Vol. 11
Open Access | Times Cited: 29
What makes SARS‐CoV‐2 unique? Focusing on the spike protein
Jingbo Qian, Shi-Chang Zhang, Fang Wang, et al.
Cell Biology International (2024) Vol. 48, Iss. 4, pp. 404-430
Open Access | Times Cited: 12
Meta-analysis of Cognitive Function Following Non-severe SARS-CoV-2 Infection
Tara Austin, Michael L. Thomas, Min Lü, et al.
Neuropsychology Review (2024)
Closed Access | Times Cited: 7
National seroepidemiological study of COVID‐19 after the initial rollout of vaccines: Before and at the peak of the Omicron‐dominant period in Japan
Takeshi Arashiro, Satoru Arai, Ryo Kinoshita, et al.
Influenza and Other Respiratory Viruses (2023) Vol. 17, Iss. 2
Open Access | Times Cited: 18
Research progress in spike mutations of SARS‐CoV‐2 variants and vaccine development
Xuemei He, Cai He, Weiqi Hong, et al.
Medicinal Research Reviews (2023) Vol. 43, Iss. 4, pp. 932-971
Open Access | Times Cited: 17
Gastrointestinal symptoms in COVID-19 and disease severity: a Japanese registry-based retrospective cohort study
Yuta Matsubara, Hiroki Kiyohara, Yohei Mikami, et al.
Journal of Gastroenterology (2024) Vol. 59, Iss. 3, pp. 195-208
Closed Access | Times Cited: 6
Longitudinal Assessment of BNT162b2- and mRNA-1273-Induced Anti-SARS-CoV-2 Spike IgG Levels and Avidity Following Three Doses of Vaccination
Jimmie Bullock, Thomas E. Hickey, Troy J. Kemp, et al.
Vaccines (2024) Vol. 12, Iss. 5, pp. 516-516
Open Access | Times Cited: 5
Google Trends applications for COVID-19 pandemic: A bibliometric analysis
Hao Li, Ning Zhang, Xingxing Ma, et al.
Digital Health (2025) Vol. 11
Open Access
Characteristics of patients with COVID-19 and smell and/or taste disorders depending on different virus strains: a cross-sectional study in Hiroshima, Japan
Yukinobu Ota, Yui Yumiya, Odgerel Chimed‐Ochir, et al.
BMJ Open (2025) Vol. 15, Iss. 2, pp. e088377-e088377
Open Access
Duration of mild acute SARS-CoV-2 infections with Omicron depending on previous vaccinations and infections – Using data of the German DigiHero cohort study from post-pandemic winters 2022/2023 and 2023/2024
Nadine Glaser, Sophie Diexer, Bianca Klee, et al.
Journal of Infection and Public Health (2025) Vol. 18, Iss. 6, pp. 102746-102746
Open Access
Protection of the third-dose and fourth-dose mRNA vaccines against SARS-CoV-2 Omicron subvariant: a systematic review and meta-analysis
Obaidur Rahman, Taro Kamigaki, Moe Moe Thandar, et al.
BMJ Open (2023) Vol. 13, Iss. 12, pp. e076892-e076892
Open Access | Times Cited: 15
Impact of COVID-19 vaccination status on hospitalization and disease severity: A descriptive study in Nagasaki Prefecture, Japan
Guoxi Cai, Shiwen Liu, Yixiao Lu, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 4
COVID-19 vaccine effectiveness against symptomatic infection and hospitalisation in Belgium, July 2021 to May 2022
Toon Braeye, Joris Adriaan Frank van Loenhout, Ruben Brondeel, et al.
Eurosurveillance (2023) Vol. 28, Iss. 26
Open Access | Times Cited: 11
Effectiveness of BA.1- and BA.4/BA.5-containing bivalent COVID-19 mRNA vaccines against symptomatic SARS-CoV-2 infection during the BA.5-dominant period in Japan
Takeshi Arashiro, Yuzo Arima, Jin Kuramochi, et al.
Open Forum Infectious Diseases (2023)
Open Access | Times Cited: 9
Long-term vaccination strategies to mitigate the impact of SARS-CoV-2 transmission: A modelling study
Alexandra B. Hogan, Sean L. Wu, Jaspreet Toor, et al.
PLoS Medicine (2023) Vol. 20, Iss. 11, pp. e1004195-e1004195
Open Access | Times Cited: 9
New variants of COVID‐19 (XBB.1.5 and XBB.1.16, the “Arcturus”): A review of highly questioned concerns, a brief comparison between different peaks in the COVID‐19 pandemic, with a focused systematic review on expert recommendations for prevention, vaccination, and treatment measures in the general population and at‐risk groups
Homa Pourriyahi, Nima Hajizadeh, Mina Khosravi, et al.
Immunity Inflammation and Disease (2024) Vol. 12, Iss. 6
Open Access | Times Cited: 3
COVID-19 and the COVID-19 Vaccine in Japan—A Review from a General Physician’s Perspective
Hiroshi Kusunoki
Pharmacoepidemiology (2023) Vol. 2, Iss. 3, pp. 188-208
Open Access | Times Cited: 7
The presence of broadly neutralizing anti-SARS-CoV-2 RBD antibodies elicited by primary series and booster dose of COVID-19 vaccine
Xiaorui Chen, Arpita Mohapatra, Hong Thuy Vy Nguyen, et al.
PLoS Pathogens (2024) Vol. 20, Iss. 6, pp. e1012246-e1012246
Open Access | Times Cited: 2
Towards the light at the end of the tunnel: Changes in clinical settings and political measures regarding COVID-19 from 2021, and future perspectives in Japan
Kohei Kamegai, Kayoko Hayakawa
Global Health & Medicine (2022) Vol. 4, Iss. 6, pp. 327-331
Open Access | Times Cited: 11
Effectiveness of messenger RNA vaccines against infection with SARS-CoV-2 during the periods of Delta and Omicron variant predominance in Japan: the Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study
Wataru Mimura, Chieko Ishiguro, Megumi Maeda, et al.
International Journal of Infectious Diseases (2022) Vol. 125, pp. 58-60
Open Access | Times Cited: 9
Potential Risk Factors to COVID-19 Severity: Comparison of SARS-CoV-2 Delta- and Omicron-Dominant Periods
Daiki Yamaguchi, Odgerel Chimed‐Ochir, Yui Yumiya, et al.
International Journal of Environmental Research and Public Health (2024) Vol. 21, Iss. 3, pp. 322-322
Open Access | Times Cited: 1
Evaluation of the effectiveness and safety of sequential vaccination with inactivated SARS‐CoV‐2 vaccine and Ad5‐nCoV booster in pediatric liver transplant recipients
Zhigang Zheng, Huimin Wu, Xiaowei Sun, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 3
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top